VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Abstract VISTA, an inhibitory myeloid-T-cell checkpoint, holds promise as a target for cancer immunotherapy. However, its effective targeting has been impeded by issues such as rapid clearance and cytokine release syndrome observed with previous VISTA antibodies. Here we demonstrate that SNS-101, a...

Full description

Bibliographic Details
Main Authors: Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H. Martin, Yoshiko Takeuchi, Kader Thiam, Robert D. Schreiber, Edward H. van der Horst
Format: Article
Language:English
Published: Nature Portfolio 2024-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-47256-x

Internet

https://doi.org/10.1038/s41467-024-47256-x

Similar Items